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Abstract
Pancreatic adenocarcinoma frequently recurs in patients even after resection with curative intent. The majority of
these are early recurrences and are associated with metastatic disease, thus not amenable to repeat resection. Here
we report a patient who underwent completion pancreatectomy for a metachronous pancreatic adenocarcinoma.
This patient initially presented with painless jaundice and computed tomography (CT) revealed a mass in the head
of the pancreas. Brushings obtained at endoscopic retrograde cholangiopancreatography (ERCP) were positive for
adenocarcinoma. This patient then underwent a Whipple procedure and final pathology demonstrated stage III
pancreatic ductal adenocarcinoma. Adjuvant therapy included gemcitabine and erlotinib. This patient was followed
with physical examinations and serial laboratory and imaging studies. There was no evidence of disease for four
years at which time and sharp elevation in CA-19-9 was found. Subsequent imaging revealed a mass in the remnant
pancreas. Curative intent completion pancreatectomy was then performed which confirmed the presence of
pancreatic adenocarcinoma. This was followed by adjuvant Gemcitabine based chemotherapy and chemoradiation.
One year later the patient is alive with no evidence of disease. Thus, in highly selected patients with recurrent or
metachronous pancreatic cancer, repeat pancreatectomy can be considered, but the course of treatment should be
considered in a multidisciplinary setting.
Background
In 2014, it was estimated that over 46,000 people would
be diagnosed with pancreatic adenocarcinoma with
greater than 39,000 patients dying from the disease [1]
making it one of the more lethal malignancies encoun-
tered. Of the subset of patients who are resectable and
undergo curative intend surgery, the majority will ultim-
ately develop recurrent disease with approximately 80 %
of recurrences occurring within the first 2 years [2, 3]
with 5-year survival rates ranging from 5 to 40 % [4–6].
These recurrences may be isolated to the pancreatic bed
or present as distant metastatic disease. Given the over-
all poor prognosis of this disease, there remains contro-
versy regarding the role of surgery in recurrent disease.
While most would agree that in patients with early re-
currence, the role of surgery is limited at best, the treat-
ment of late recurrences or metachronous tumors in the
pancreatic remnant is less clear. Because the late devel-
opment of a metachronous tumor, particularly one iso-
lated to the pancreatic remnant is a relatively rare event,
the role of surgery may be more easily justified. Here, a
case is presented of a patient who developed a meta-
chronous adenocarcinoma of the pancreas 4 years after
the initial diagnosis of stage III pancreatic cancer, treated
with upfront curative intent completion pancreatectomy
followed by adjuvant chemotherapy and chemoradiation.
Case presentation
In February 2010, a then 69-year-old female presented
to her family physician with weight loss, early satiety
and jaundice without abdominal pain, nausea, or vomit-
ing. She was otherwise in excellent medical condition
with her only significant past medical or surgical history
being cervical carcinoma in situ treated with hysterec-
tomy at age 29. She had no history of smoking and used
alcohol only on rare social occasions. In addition, there
was no family history of any malignant disease. Her
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initial workup included laboratory investigations that
were significant for hyperbilirubinemia of 8.7 mcg/dL.
This was followed by computed tomography (CT) of the
abdomen and pelvis that revealed significant intra- and ex-
trahepatic ductal dilatation (Fig. 1a) and a 2.69 × 2.64 cm
mass in the head of the pancreas (Fig. 1b). There was no
evidence of peripancreatic, periportal, mesenteric, or
celiac axis adenopathy, nor was there evidence of distant
metastatic disease. In addition, there was no abutment on
the mass to the portal vein or the superior mesenteric
artery and vein. Based on these initial CT findings, this
was a resectable pancreatic head mass.
Her workup continued with endoscopic ultrasound
(EUS) and endoscopic retrograde cholangiopancreato-
graphy (ERCP). These studies confirmed the presence of a
mass within the head of the pancreas and demonstrated a
2-cm distal common bile duct stricture. Brushings of this
area confirmed the presence of adenocarcinoma.
The patient was then referred for a surgical oncology
evaluation. Repeat CT of the chest, abdomen, and pelvis
was consistent with her original scan and showed no evi-
dence of metastatic disease. Her CA 19-9 was checked
and found to be elevated at 441 U/mL. Her case was dis-
cussed in a multidisciplinary tumor board, and because
she appeared to be resectable at presentation, surgery ra-
ther than neoadjuvant therapy was offered.
In March of 2010, she was taken to the operating
room where diagnostic laparoscopy revealed no evidence
of metastasis and a classic pancreaticoduodenectomy
was performed. Surgical pathology from the specimen
showed a moderately differentiated infiltrating ductal
adenocarcinoma of the pancreatic head. The tumor mea-
sured 4.2 × 3.0 × 2.6 cm and invaded into the peripan-
creatic soft tissue, though all margins were negative with
the closest margin being 0.3 cm. Angiolymphatic inva-
sion was identified. Two of 16 lymph nodes were posi-
tive for metastatic disease. Per the American Joint
Committee on Cancer (AJCC) staging guidelines [7], this
was a T3N1b, stage III pancreatic cancer. There was no
evidence that this tumor was arising from a premalig-
nant lesion such as an intraductal papillary mucinous
neoplasm (IPMN). In addition, there was no mention of
pancreatic intraepithelial neoplasia (PanIN) within the
pancreas or at the margin in the original pathology
report.
Postoperatively, she received adjuvant therapy with
3 cycles of gemcitabine monotherapy followed by an
additional 3 cycles of gemcitabine with erlotinib. She
underwent routine follow-up with physical examination,
imaging, and laboratory studies on a semiannual basis.
From late 2010 after completing adjuvant therapy until
March 2014, she showed no evidence of disease with
multiple negative imaging studies and CA19-9 levels
ranging from 12.1 to 44.5 U/mL. In March 2014, how-
ever, her CA 19-9 increased to 161.4 U/mL. A CT done
at this time (Fig. 2) showed a 2.1 × 2 cm mass in the
body of the pancreas suspicious for recurrent or meta-
chronous tumor. By CT, there was no evidence of dis-
ease outside of the pancreas. The CT was followed by
PET-CT (Fig. 3) that demonstrated this PET avid lesion
in the pancreas with a maximum SUV of 5.9 g/mL with
no evidence of metastatic disease, again suspicious for
pancreatic cancer. The patient’s case was presented at a
multidisciplinary tumor conference with discussions on
how to proceed with treatment, with the main questions
focused on neoadjuvant therapy versus resection fol-
lowed by adjuvant therapy if the mass is proven to be
pancreatic carcinoma. Because of the long disease-free
interval and the fact that the mass appeared resectable,
the tumor board’s recommendation was to proceed with
surgery first.
In June 2014, the patient underwent a diagnostic lapar-
oscopy that did not reveal evidence of disseminated dis-
ease, followed immediately by exploratory laparotomy
Fig. 1 Representative cuts of the patient’s initial CT scan demonstrating intrahepatic biliary ductal dilatation (a) and a heterogeneous mass within
the head of the pancreas (b)
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with completion total pancreatectomy with splenectomy.
This procedure lasted just over 3 h and was completed
with minimal blood loss.
Surgical pathology from this operation demonstrated
moderately differentiated ductal adenocarcinoma of the
pancreas measuring 3.2 × 2.3 × 2.1 cm. All margins were
negative. All lymph nodes evaluated (n = 7) were nega-
tive for metastatic disease. Based on AJCC staging cri-
teria, this metachronous tumor was T2N0 or stage IIB.
The patient’s hospital course was uncomplicated, and
she was discharged home on postoperative day 7.
Following surgery, she received adjuvant therapy con-
sisting of 3 cycles of gemcitabine. This was followed by
chemoradiation that included 45 Gy in 25 fractions with
concurrent capecitabine. She completed adjuvant ther-
apy in October 2014, and as of March 2015, she has
no clinical evidence of disease recurrence(Fig. 4) and
a Ca19-9 of 28.5.
Discussion
Invasive ductal carcinoma of the pancreas remains one
of the most incurable malignancies with poor overall
survival and high recurrence rates despite aggressive sur-
gical and adjuvant therapies. Most of these recurrences
occur within the first 2 years and are associated with
distant metastatic disease, limiting the role of repeat
surgery.
That said, there are rare cases of late recurrences or
metachronous lesions that are resectable. There is, how-
ever, limited data in the literature to guide treatment for
these patients. Much of the literature regarding repeat
pancreatectomy for recurrent pancreatic cancer has been
limited to case reports. Over the last 10 years, eight add-
itional cases have been described [8–12]. Details of these
other case reports are outlined in Table 1.
In addition to these case reports, there have been
sporadic retrospective reviews of treatment for recurrent
pancreatic carcinoma.
The first of these published by Kleef et al. [13] in-
cluded 30 patients with recurrent pancreatic ductal
carcinoma, 15 who underwent repeat curative intent sur-
gery, and 15 who did not have a repeat resection. The
median time from initial surgery to recurrence was
12 months. Data from this study showed a median
survival of 17 months in the group that was resected
compared to 9.4 months in those who were not, with
statistically significant survival improvement in those pa-
tients who were resected after a disease-free interval of
greater than 9 months. A subsequent study by Lavu et
al. [14] looked at a series of 11 patients from a single in-
stitution that underwent repeat pancreatectomy. Of
these, six were for recurrent pancreatic ductal
Fig. 2 Representative cut of the patient’s CT scan in March of 2013,
4 years after the initial surgery. This demonstrates a mass within the
pancreatic remnant suspicious for carcinoma
Fig. 3 PET (a) and PET-CT (b) images demonstrating the mass within the pancreatic remnant with no evidence of metastatic disease
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adenocarcinoma. They reported minimal complications
and a median survival of 17.5 months.
A third, larger study from Germany [15] examined a
series of 97 patients with pancreatic cancer recurrence.
Of these, 57 had an isolated local recurrence and 41
were found to be resectable. In this study, there was a
significant survival advantage in those undergoing repeat
resection with median survival of 16.4 versus 9.4 months
in those that were resectable or unresectable, respect-
ively. In addition, these authors found that the ability to
achieve an R0 resection was critical. The 16 patients
who had an R0 resection at the second operation had a
median survival of 30 months.
The most recent study evaluating the role of repeat
pancreatectomy for recurrent pancreatic cancer by
Miyazaki et al. [16] evaluated 170 patients from Japan
with recurrent pancreatic cancer. Sixty-seven of these
had isolated recurrences within the pancreatic remnant
and 11 ultimately underwent re-resection. Consistent
with the previous reports, they found improved median
survival of 25 months with repeat resection versus
9.3 months in those not resected.
While these four studies all show similar results, with
improved median survival in resectable cases of recur-
rent pancreatic cancer, there is some conflicting data in
the literature. In particular, a study from MD Anderson
Cancer Center [17] looked at the results of selective op-
eration for locally recurrent or metastatic pancreatic
cancer. This study showed little benefit in resecting local
recurrences in the pancreas even after a disease-free
interval on over 20 months. This study only demon-
strated a benefit for metastasectomy of lung metastases
in select patients with long disease-free interval.
One difficulty in evaluating patients who develop can-
cer in the remnant pancreas is determining if it repre-
sents local recurrence or a second primary. Previous
studies have shown that the rate of multifocal carcin-
omas within the pancreas may as high as 32 % [18], and
microscopic secondary lesions may contribute to the
high rates of rapid local recurrence frequently seen with
this disease. In addition, up to 16 % of patients will
develop second cancers in the pancreas even after
disease-free survival after surgery of 5 years [3]. While it
is difficult to determine weather cancer in the remnant
pancreas is a local recurrence or metachronous second
primary, in the case presented here, we favor that this
was a true second primary. This is largely due to a long
disease-free interval with no rise in the patient’s tumor
markers until the second tumor developed.
New advancements in the use of adjuvant and neoad-
juvant chemotherapy and radiation have improved sur-
vival in pancreatic cancer. However, there remains some
controversy regarding the sequencing of therapy for
Table 1 Case reports of remnant pancreatectomy
Patient no. Author Age Gender Initial surgery DFI (months)a Second surgery Follow-up
1 Dalla Valle et al. [9] 63 Male PDb 12 DP Alive, 24 months
2 Takamatsu et al. [8] 63 Male PD 43 DP Alive, 10 months
3 Miura et al. [10] 72 Female PD 29 DP plus liver resection Dead, 5 months
4 Miura et al. [10] 52 Female PD 22 DP Dead, 44 months
5 Koizumi et al. [11] 65 Male PD 85 DP Alive, 10 months
6 Koizumi et al. [11] 67 Male DPc 25 Proximal remnant pancreatectomy Alive, 8 months
7 Ogino et al. [12] 63 Female PD 66 DP Alive, 13 months
8 Ogino et al. [12] 56 Male PD 37 DP Alive, 7 months




Fig. 4 Follow-up CT 11 months after completion pancreatectomy.
At this point, the patient has completed adjuvant chemotherapy
and chemoradiation and there is no evidence of disease
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patients who develop recurrent disease within the
pancreatic remnant. The NCCN has no clear guidelines
regarding surgical treatment of pancreatic remnant car-
cinoma [19]. In the case presented here, it was felt that
curative intent surgery should be attempted as the first-
line therapy as there was no evidence of CT or PET-CT
of metastatic disease and the lesion appeared completely
resectable. In addition, the long disease-free interval sug-
gested an indolent disease course that could potentially
be cured with surgery. Postoperative chemotherapy and
chemoradiation was given in the adjuvant setting and
has resulted in the patient being disease free now for
11 months.
Conclusions
In conclusion, remnant pancreatectomy remains safe and
can result in prolonged disease-free survival in highly se-
lected patients with cancer in the remnant pancreas after
previous surgery for pancreatic adenocarcinoma. While
the case reported here has resulted in no disease recur-
rence to date, the short follow-up precludes us from draw-
ing any conclusions about cure in this patient.
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